Systematic Review and Meta-Analysis of Drug-Coated Balloon Angioplasty for In-Stent Restenosis in Femoropopliteal Artery Disease

Zhen, Yanhua; Ren, Haiyan; Chen, Jie; Chang, Zhihui; Wang, Chuanzhuo; Zheng, Jiahe

doi:10.1016/j.jvir.2021.12.007

Cited by 9 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high level of occlusion (such as suprainguinal disease) and single stage multisegmented revascularization are high risk of perioperative MACE due to rapidly decreasing of afterload and rapid increasing of blood flow to lower limbs (Figure 6) [41,42]. In addition, the new technology of the antiproliferative agent embeds endovascular device which has increased the patency of the target arterial lesion are increasing to use in CLTI patients who undergo ET [21][22][23][24][25][26]. Some cohort study and meta-analysis report the high incidence of MACE in CLTI patients after revascularization by DCB and DES.…”

Section: Mace Related To Endovascular Treatmentmentioning

confidence: 99%

“…The drug delivering technology of the paclitaxel, sirolimus, everolimus and other antiproliferative agent coated balloon and eluting stent to increase the patency of native artery and in-stent restenosis (ISR) through the aggressively inhibition of arterial damage induced neointimal hyperplasia are trending to increase for ET in patient with CLTI [21][22][23][24][25][26]. Due to the controversy of the MACE and potential complications related to DCB, and DES, the pharmacologic effect of drug-delivering technology and pathophysiology of MACE are very important to guide the individual patients-based approach and determine the strategies to offer the drug delivering technology in CLTI patients who undergo ET [30,32,33].…”

Section: Drug-delivering Technology Concept and Their Effect On The P...mentioning

confidence: 99%

“…Therefore, the significant recurrent stenosis of the ISR Cardiovascular Complications Related to Lower Limb Revascularization and Drug-Delivering… DOI: http://dx.doi.org/10.5772/intechopen.107973 lesions usually presents after POBA without any specialty device [51,53]. The DCB appears to be a significant benefit to treating ISR as opposed to POBA [21,56,71]. The combination of DCB with atherectomy devices is offered to increase the patency in patients with ISR.…”

Section: Strategies For Drug-delivering Technology and Concept In End...mentioning

confidence: 99%

“…Recently, the novel technology developed the antiproliferative agent -coated and -eluting device which can deliver the drugs to the vessel wall to limit the neointimal growth within de novo vascular system and stent [21][22][23][24][25][26]. However, some literatures report the MACE, aneurysmal degeneration, vascular fibrinoid necrosis, small vessel inflammation, and budget impact after drug technology device including drug coated balloon (DCB) and drug eluting stent (DES) in patients with ET [27][28][29][30][31].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cardiovascular Complications Related to Lower Limb Revascularization and Drug-Delivering Technology in Peripheral Arterial Disease

Orrapin¹

2023

Novel Pathogenesis and Treatments for Cardiovascular Disease

View full text Add to dashboard Cite

The cardiovascular complication related to lower limb revascularization is the common cause of mortality in patients with peripheral arterial disease (PAD). The coexisting multisite atherosclerotic vascular disease is increasing risk of major adverse cardiovascular events (MACE). The minimally invasive approach for revascularization, namely, endovascular-first strategy for decreasing risk of intervention is the modern approach. The novel technology of the drug delivering device by paclitaxel, sirolimus, and other antiproliferative drug coated balloon (DCB) and drug eluting stent (DES) to increase the patency of the target artery are trending to use in patients with CLTI. However, the long-term result and safety of a drug delivering device are still controversial. The paclitaxel related to MACE and major adverse limb events (MALE) need to be investigated. The new drug coating balloon, sirolimus demonstrated the excellent short-term result. However, there are some limitations of previous randomized studies and meta-analyses to conclude the best strategy and device to perform the best result for revascularization without increasing risk of MACE and MALE in CLTI patients who candidate for revascularization. This article is summarized the pathophysiology of MACE and MALE in the patients with PAD during revascularization, paclitaxel related cardiovascular complications and sirolimus coated balloon.

show abstract

Section: Mace Related To Endovascular Treatmentmentioning

confidence: 99%

Section: Drug-delivering Technology Concept and Their Effect On The P...mentioning

confidence: 99%

Section: Strategies For Drug-delivering Technology and Concept In End...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cardiovascular Complications Related to Lower Limb Revascularization and Drug-Delivering Technology in Peripheral Arterial Disease

Orrapin¹

2023

Novel Pathogenesis and Treatments for Cardiovascular Disease

View full text Add to dashboard Cite

show abstract

“…Currently, two main methods are used for interventional treatment of femoropopliteal artery disease, namely, stent implantation and balloon dilation (4) followed by strict medical therapy, including long-term antiplatelet therapy and statin (6). In recent years, drug-coated balloon (DCB) has been gradually applied in the treatment of femoropopliteal artery disease, especially restenosis after stent implantation (7)(8)(9)(10). With the increasing application of DCB, the number of direct uses of DCB to treat femoropopliteal artery disease has also increased significantly (11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study

Wang¹,

Lei²,

Gu³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundPeripheral artery disease (PAD) is a common atherosclerotic vascular disease. The use of drug-coated balloon (DCB) for the treatment of femoropopliteal artery disease has gradually increased. A certain percentage of patients developed target lesion restenosis after DCB treatment of the femoral popliteal artery. The neutrophil-to-lymphocyte ratio (NLR) is closely related to the level of inflammatory activity and has predictive value for atherosclerotic vascular disease. This study aimed to analyze the relationship between NLR and 1-year restenosis after DCB for femoropopliteal artery disease.MethodsPatients with femoropopliteal artery disease who were treated with DCBs at our hospital from May 2016 to December 2020 were retrospectively included. Baseline data during the patient’s first hospital stay and data during follow-up were collected. Demographic data, laboratory test results, lesion examination results, and major adverse events during the follow-up period were collected. Logistic regression was used to analyze the factors associated with restenosis after DCB.ResultsA total of 117 patients were included. During 1-year follow-up, 19 cases (16.2%) of restenosis were detected. Five of these patients (4.3% of total included patients) were readmitted for symptomatic ischemia. No deaths or amputations occurred. Baseline NLR in patients with restenosis was higher than that in patients without restenosis (2.4 (2.1, 3.4) vs. 1.8 (1.3, 2.3), P < 0.001). Logistic univariate and multivariate analysis showed that baseline hs-CRP level (OR = 1.10, 95%CI: 1.05–1.34), lesion length (OR = 1.04, 95%CI: 1.02–1.27), use of rivaroxaban (OR = 1.08, 95%CI: 1.05–1.39), NLR (OR = 1.47, 95%CI: 1.13–2.48), LDL-C level (OR = 1.25, 95%CI: 1.05–1.52), and diabetes (OR = 1.25, 95%CI: 1.05–1.52) = 1.18, 95%CI: 1.06–1.66) were predictors of restenosis.ConclusionBaseline NLR before DCB can predict the risk of restenosis after surgery.

show abstract

Strukturierte Nachsorge nach peripherer Katheterintervention

Tiepner,

Weiss

2024

Klinische Angiologie

View full text Add to dashboard Cite

Systematic Review and Meta-Analysis of Drug-Coated Balloon Angioplasty for In-Stent Restenosis in Femoropopliteal Artery Disease

Cited by 9 publications

References 29 publications

Cardiovascular Complications Related to Lower Limb Revascularization and Drug-Delivering Technology in Peripheral Arterial Disease

Cardiovascular Complications Related to Lower Limb Revascularization and Drug-Delivering Technology in Peripheral Arterial Disease

Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study

Strukturierte Nachsorge nach peripherer Katheterintervention

Contact Info

Product

Resources

About